[
    [
        {
            "time": "2019-09-08",
            "original_text": "复星医药（02196.HK）：复宏汉霖已向香港联交所呈交经更新聆讯后资料集",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "香港联交所",
                    "聆讯后资料集"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药（02196.HK）：复宏汉霖已向香港联交所呈交经更新聆讯后资料集",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-09-08",
            "original_text": "华鑫证券：医药生物板块业绩增长稳健 配置价值显著",
            "features": {
                "keywords": [
                    "华鑫证券",
                    "医药生物",
                    "业绩增长",
                    "配置价值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华鑫证券：医药生物板块业绩增长稳健 配置价值显著",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-09-08",
            "original_text": "复星医药（02196.HK）：复宏汉霖拟为汉霖制药不超1.7亿元融资提供担保 大额借贷担保",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "汉霖制药",
                    "融资",
                    "担保"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药（02196.HK）：复宏汉霖拟为汉霖制药不超1.7亿元融资提供担保 大额借贷担保",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-09-08",
            "original_text": "仿制药一致性评价势在必行，又有多家药企品种过评",
            "features": {
                "keywords": [
                    "仿制药",
                    "一致性评价",
                    "药企",
                    "过评"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "仿制药一致性评价势在必行，又有多家药企品种过评",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-08",
            "original_text": "港股早知道：九月红包行情进行中 概念股继续飞舞",
            "features": {
                "keywords": [
                    "港股",
                    "九月红包",
                    "行情",
                    "概念股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股早知道：九月红包行情进行中 概念股继续飞舞",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-09-08",
            "original_text": "【山证医药】医药行业周报（20190908）：建议持续关注医保目录谈判与“4+7”带量采购扩面",
            "features": {
                "keywords": [
                    "山证医药",
                    "医保目录",
                    "4+7",
                    "带量采购",
                    "扩面"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【山证医药】医药行业周报（20190908）：建议持续关注医保目录谈判与“4+7”带量采购扩面",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]